Your browser is no longer supported. Please, upgrade your browser.
Settings
THOR Synthorx, Inc. daily Stock Chart
THOR [NASD]
Synthorx, Inc.
Index- P/E- EPS (ttm)-2.02 Insider Own17.00% Shs Outstand33.81M Perf Week-3.97%
Market Cap523.72M Forward P/E- EPS next Y-2.06 Insider Trans- Shs Float29.26M Perf Month-13.46%
Income-65.30M PEG- EPS next Q-0.38 Inst Own86.10% Short Float3.95% Perf Quarter-26.06%
Sales- P/S- EPS this Y-831.80% Inst Trans1.62% Short Ratio9.26 Perf Half Y-
Book/sh5.54 P/B2.80 EPS next Y-24.80% ROA-61.30% Target Price28.75 Perf Year-
Cash/sh5.30 P/C2.92 EPS next 5Y- ROE-87.30% 52W Range11.00 - 23.53 Perf YTD-10.87%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-34.16% Beta-
Dividend %- Quick Ratio22.20 Sales past 5Y- Gross Margin- 52W Low40.82% ATR1.20
Employees39 Current Ratio22.20 Sales Q/Q- Oper. Margin- RSI (14)39.52 Volatility6.08% 7.98%
OptionableNo Debt/Eq0.00 EPS Q/Q-376.60% Profit Margin- Rel Volume0.51 Prev Close15.54
ShortableYes LT Debt/Eq0.00 EarningsMar 28 AMC Payout- Avg Volume124.63K Price15.49
Recom1.50 SMA20-5.32% SMA50-15.99% SMA200-9.05% Volume64,714 Change-0.32%
Jan-02-19Initiated Jefferies Buy $21
Jan-02-19Initiated H.C. Wainwright Buy $30
May-15-19 05:15PM  Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-30-19 05:49PM  Synthorx: 1Q Earnings Snapshot Associated Press -5.96%
04:05PM  Synthorx Reports First Quarter Financial Results GlobeNewswire
Apr-23-19 07:00AM  3 Top Stocks That Aren't on Wall Street's Radar Motley Fool
Apr-02-19 08:00AM  Synthorx to Present at H.C. Wainwright Global Life Sciences Conference in London GlobeNewswire
Mar-19-19 08:00AM  Synthorx to Present at the American Association of Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Mar-12-19 05:38PM  Synthorx: 4Q Earnings Snapshot Associated Press
04:05PM  Synthorx Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
08:00AM  Synthorx to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy GlobeNewswire
Feb-25-19 12:41PM  Small Cap Winners And Losers From Last Week Benzinga
Feb-21-19 04:05PM  Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire -9.89%
Dec-20-18 08:00AM  Synthorx Appoints Andrew Powell, J.D., to its Board of Directors GlobeNewswire
Dec-12-18 04:05PM  Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +9.73%
Dec-06-18 09:15PM  Synthorx Announces Pricing of Initial Public Offering GlobeNewswire
04:00PM  Stocks pare losses, Nasdaq closes in the green Yahoo Finance
Dec-02-18 05:01PM  IPO Outlook For The Week: Proteins, Fashion And Finance Benzinga
Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.